{"id":"NCT01318070","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","officialTitle":"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-11","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2011-03-18","resultsPosted":"2011-07-06","lastUpdate":"2012-02-03"},"enrollment":339,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin and pioglitazone","otherNames":["Alogliptin (SYR-322)","Pioglitazone: Actos®"]},{"type":"DRUG","name":"Alogliptin and pioglitazone","otherNames":["Alogliptin (SYR-322)","Pioglitazone: Actos®"]},{"type":"DRUG","name":"Pioglitazone","otherNames":["Pioglitazone: Actos®"]}],"arms":[{"label":"Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD","type":"EXPERIMENTAL"},{"label":"Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD","type":"EXPERIMENTAL"},{"label":"Pioglitazone (15mg or 30mg ) QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (Week 12).","timeFrame":"Baseline and Week 12.","effectByArm":[{"arm":"Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD","deltaMin":-0.91,"sd":0.441},{"arm":"Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD","deltaMin":-0.97,"sd":0.517},{"arm":"Pioglitazone 15 mg or 30 mg QD","deltaMin":-0.19,"sd":0.552}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"33 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":111},"commonTop":["Nasopharyngitis","Blood creatine phosphokinase increased","Dental caries"]}}